Clinics & Inpatient Care Units
Hemophilia Comprehensive Care Program
August 2018 enewsletter
Subject: Product Switch update
We hope you all are enjoying the summer.
Some of you have had to switch from one factor VIII or factor IX product to an alternative one, because of the contracts recently signed by Canadian Blood Services. Our progress in making these product switches has been good. About 80 per cent of all patients have already changed their product, with no unexpected problems or adverse events. We hope to finish this project in the near future.
We can promise you that you will continue to have full access to a safe, effective, state-of-the-art hemophilia replacement product, at no charge to you. We know that change is difficult and the time commitment involved in selecting and switching to a new product is cumbersome. The clinic staff appreciate your assistance in making this a smooth transition.
Pharmacokinetic (PK) assessment is used to help personalize your individual factor VIII or IX treatment plan (dose and schedule). This is to guide your care; it is not a research study.
Since your response to a particular factor may be different than your previous one, we suggest that PK testing be done after you switch to a different product. PK assessment requires an infusion of factor and some blood work to be drawn at specific time intervals following the infusion. We can then calculate your response to that specific product. We will also want to do a blood test to screen for inhibitors three to six months after transitioning to a new product.Finally, Georgina, our hemophilia case manager, will be away on medical leave for a few months. In the meantime Grace, who many of you know, will be filling that role temporarily. Grace will be assisted by other nurses who you may have seen in our clinic, Alice and Ekaterina (who is now the nurse-educator for the ambulatory clinics). We all wish Georgina a speedy recovery!
Web Archive of Email Updates
You can always browse our email update archive here.
Thanks for reading,The St. Michael’s Hemophilia Team